A new way of thinking about academia-industry collaboration — a BioCentury podcast

Takeaways from the 2nd BioCentury Grand Rounds R&D conference

With federal funding at risk and VCs increasingly focused on de-risked assets, academia is facing unprecedented headwinds despite rapid advancements in innovation.

One potential bright spot: Pharma, which is turning to academia to access first-in-class innovation. But many in pharma complain it is difficult to work with academia.

On a special Grand Rounds edition of the BioCentury This Week podcast, BioCentury analysts and special guests discuss a new way of thinking and a new era of collaboration between academia and industry.

BioCentury’s 2nd Grand Rounds-U.S. R&D conference in Chicago brought together academic innovators, pharma leaders and investors last week to debate key bottlenecks in translation, explore cutting-edge science and chart a new path forward.

Edward Hodgkin, managing partner of Syncona Ltd. (LSE:SYNC), and Michelle Hoffmann, executive director of the Chicago Biomedical Consortium, joined BioCentury’s analysts on stage in Chicago to wrap up Grand Rounds and discuss key takeaways from the event.